NCT01855230View on ClinicalTrials.gov

Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
COPD
Interventions
DRUG

ASM-024

ASM-024 b.i.d for 14 days

DRUG

Placebo

Placebo b.i.d. for 14 days

Trial Locations (1)

G1V 4G5

Institut universitaire de cardiologie et de pneumologie de Québec, Québec

All Listed Sponsors
lead

Asmacure Ltée

INDUSTRY

NCT01855230 - Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter